1066.HK

Shandong Weigao Group Medical Polymer Company Limited [1066.HK] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

1066.HK Stock Summary

EPS has been increasing for the past 3 years (Yearly statements)

1066.HK has more than 3 years of cash runway (45 months)

Earnings are expected to fall -100% next year

Top 10 Correlated Stocks

1066.HK

In the News

1066.HK Financial details

Company Rating

Strong Buy

Market Cap

21.53B

Income

2.46B

Revenue

13.54B

Book val./share

4.89

Cash/share

1.57

Dividend

0.17

Dividend %

2.88%

Employees

12.52K

Optionable

Shortable

Yes

Earnings

28 Mar 2024

P/E

9.6

Forward P/E

PEG

16.32

P/S

1.81

P/B

1.21

P/C

3.03

P/FCF

22.49

Quick Ratio

1.24

Current Ratio

3.05

Debt / Equity

0.2

LT Debt / Equity

0.15

EPS (TTM)

0.54

EPS next Y

EPS next Q

EPS this Y

17.65%

EPS next Y

EPS next 5Y

EPS last 5Y

12.7%

Revenue last 5Y

9.11%

Revenue Q/Q

EPS Q/Q

SMA20

SMA50

SMA100

-37.5%

Inst Own

Inst Trans

ROA

ROE

13%

ROC

0.13%

Gross Margin

52%

Oper. Margin

26%

Profit Margin

20%

Payout

27%

Shs Outstand

Shs Float

Target Price

52W Range

4.3-14.18

52W High

-66%

52W Low

+19%

RSI

Rel Volume

0.95

Avg Volume

9.19M

Volume

8.78M

Perf Week

1.71%

Perf Month

-2.46%

Perf Quarter

-30.91%

Perf Half Y

-30.91%

Beta

0.439

Volatility

0.03%, 0.18%

Prev Close

-0.42%

Price

4.76

Change

-4.42%

1066.HK Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric	2018-12-31	2019-12-31	2020-12-31	2021-12-31	2022-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	1.97	2.32	2.53	2.92	3.02
Net income per share	0.33	0.41	0.46	0.51	0.6
Operating cash flow per share	0.5	0.52	0.6	0.67	0.49
Free cash flow per share	0.32	0.3	0.38	0.43	0.24
Cash per share	0.93	1.04	1.33	1.57	1.63
Book value per share	3.24	3.62	3.91	4.28	4.81
Tangible book value per share	2.02	2.53	2.95	3.5	4.01
Share holders equity per share	3.24	3.62	3.91	4.28	4.81
Interest debt per share	1.26	1.32	1	0.95	1.04
Market cap	24.9B	37.33B	66.11B	35.74B	51.01B
Enterprise value	26.43B	38.61B	64.92B	33.25B	48.64B
P/E ratio	16.91	20.24	31.68	15.7	18.73
Price to sales ratio	2.83	3.6	5.83	2.72	3.75
POCF ratio	11.22	16.08	24.52	11.78	23.03
PFCF ratio	17.49	27.94	38.87	18.63	46.44
P/B Ratio	1.72	2.31	3.77	1.86	2.35
PTB ratio	1.72	2.31	3.77	1.86	2.35
EV to sales	3	3.73	5.72	2.53	3.57
Enterprise value over EBITDA	10.13	11.63	19.68	8.23	11.15
EV to operating cash flow	11.91	16.64	24.07	10.96	21.96
EV to free cash flow	18.56	28.9	38.16	17.33	44.28
Earnings yield	0.06	0.05	0.03	0.06	0.05
Free cash flow yield	0.06	0.04	0.03	0.05	0.02
Debt to equity	0.37	0.34	0.25	0.21	0.21
Debt to assets	0.22	0.21	0.16	0.14	0.14
Net debt to EBITDA	0.58	0.39	-0.36	-0.62	-0.54
Current ratio	3.22	2.77	3.14	3.15	3.05
Interest coverage	7.2	6.83	14.57	23.62	18.61
Income quality	1.25	1.03	1.08	1.07	0.67
Dividend Yield	0.01	0.02	0.01	0.02	0.01
Payout ratio	0.15	0.39	0.34	0.29	0.27
Sales general and administrative to revenue	0.11	0.1	0.09	0.08	0.08
Research and developement to revenue	0.04	0.04	0.04	0.04	0.04
Intangibles to total assets	0.26	0.22	0.19	0.17	0.16
Capex to operating cash flow	-0.36	-0.42	-0.37	-0.37	-0.5
Capex to revenue	-0.09	-0.1	-0.09	-0.08	-0.08
Capex to depreciation	-1.41	-1.61	-1.44	-1.54	-1.39
Stock based compensation to revenue	0	0	0	0.01	0.01
Graham number	4.9	5.79	6.39	6.98	8.09
ROIC	0.09	0.11	0.1	0.12	0.12
Return on tangible assets	0.08	0.09	0.09	0.09	0.1
Graham Net	-0.91	-0.18	0.36	0.52	0.68
Working capital	7.39B	8.05B	9.63B	11B	12.16B
Tangible asset value	9.06B	11.33B	13.24B	15.76B	18.09B
Net current asset value	1.92B	3.27B	5.17B	6.65B	8.34B
Invested capital	0.37	0.34	0.25	0.21	0.21
Average receivables	0	2.17B	4.72B	5.15B	5.46B
Average payables	877.15M	1.13B	1.53B	1.79B	1.77B
Average inventory	970.96M	1.19B	1.37B	1.62B	2.02B
Days sales outstanding	0	152.91	164.17	144.07	153.71
Days payables outstanding	111.07	116.09	137.25	107.56	101.53
Days of inventory on hand	121.39	117.52	112.32	107.63	129.9
Receivables turnover	0	2.39	2.22	2.53	2.37
Payables turnover	3.29	3.14	2.66	3.39	3.6
Inventory turnover	3.01	3.11	3.25	3.39	2.81
ROE	0.1	0.11	0.12	0.12	0.13
Capex per share	-0.18	-0.22	-0.22	-0.25	-0.25

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric	2022-06-30	2022-09-30	2022-12-31	2023-03-31	2023-06-30
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.79	0.74	0.74	0.77	0.77
Net income per share	0.17	0.14	0.14	0.13	0.13
Operating cash flow per share	0.13	0.13	0.13	0.12	0.12
Free cash flow per share	0.13	0.01	0.01	0.12	0.12
Cash per share	1.59	1.63	1.63	1.57	1.57
Book value per share	4.58	4.8	4.8	4.89	4.89
Tangible book value per share	3.78	4.04	4.01	4.02	4.02
Share holders equity per share	4.58	4.8	4.8	4.89	4.89
Interest debt per share	0.99	0.75	1.03	0.74	1
Market cap	35.04B	43.17B	51.06B	49.42B	42.66B
Enterprise value	32.79B	36.3B	48.69B	42.86B	40.44B
P/E ratio	11.51	17.07	20.19	20.63	17.81
Price to sales ratio	9.9	12.99	15.37	14.33	12.37
POCF ratio	61.88	73.86	87.37	88.48	76.37
PFCF ratio	61.88	869.83	1.03K	88.48	76.37
P/B Ratio	1.7	1.99	2.36	2.24	1.94
PTB ratio	1.7	1.99	2.36	2.24	1.94
EV to sales	9.26	10.93	14.66	12.43	11.73
Enterprise value over EBITDA	34.36	40.25	53.99	51.45	48.55
EV to operating cash flow	57.92	62.12	83.31	76.74	72.41
EV to free cash flow	57.92	731.55	981.14	76.74	72.41
Earnings yield	0.02	0.01	0.01	0.01	0.01
Free cash flow yield	0.02	0	0	0.01	0.01
Debt to equity	0.22	0.16	0.21	0.15	0.2
Debt to assets	0.14	0.1	0.14	0.1	0.13
Net debt to EBITDA	-2.35	-7.61	-2.63	-7.87	-2.66
Current ratio	2.99	3.05	3.05	2.84	2.84
Interest coverage	0	0	5.3	0	4.41
Income quality	0.74	0.92	0.92	0.93	0.93
Dividend Yield	0	0.01	0.01	0	0
Payout ratio	0	0.59	0.59	0	0
Sales general and administrative to revenue	0.08	0.09	0.09	0.08	0.08
Research and developement to revenue	0.04	0.06	0.06	0.04	0.04
Intangibles to total assets	0.16	0.16	0.16	0.16	0.16
Capex to operating cash flow	0	-0.92	-0.92	0	0
Capex to revenue	0	-0.16	-0.16	0	0
Capex to depreciation	0	-2.66	-2.66	0	0
Stock based compensation to revenue	0.01	0.01	0.01	0	0
Graham number	4.17	3.89	3.89	3.82	3.82
ROIC	0.03	0.03	0.02	0.02	0.02
Return on tangible assets	0.03	0.02	0.02	0.02	0.02
Graham Net	0.51	0.68	0.68	0.66	0.66
Working capital	11.76B	12.16B	12.16B	12.15B	12.15B
Tangible asset value	17.03B	18.23B	18.09B	18.11B	18.11B
Net current asset value	7.35B	8.34B	8.34B	8.4B	8.4B
Invested capital	0.22	0.16	0.21	0.15	0.2
Average receivables	0	5.89B	5.74B	6.28B	6.82B
Average payables	0	1.81B	1.77B	1.91B	2.04B
Average inventory	0	2.09B	2.32B	2.31B	2.31B
Days sales outstanding	153.8	155.39	155.39	177.85	177.85
Days payables outstanding	101.41	100.71	105.89	107.39	111.54
Days of inventory on hand	100.05	135.48	135.48	123.97	123.97
Receivables turnover	0.59	0.58	0.58	0.51	0.51
Payables turnover	0.89	0.89	0.85	0.84	0.81
Inventory turnover	0.9	0.66	0.66	0.73	0.73
ROE	0.04	0.03	0.03	0.03	0.03
Capex per share	0	-0.12	-0.12	0	0

1066.HK Dividend History

1066.HK Frequently Asked Questions

What is Shandong Weigao Group Medical Polymer Company Limited stock symbol ?

Shandong Weigao Group Medical Polymer Company Limited is a CN stock and trading under the symbol 1066.HK

What is Shandong Weigao Group Medical Polymer Company Limited stock quote today ?

Shandong Weigao Group Medical Polymer Company Limited stock price is $4.76 today.

Is Shandong Weigao Group Medical Polymer Company Limited stock public?

Yes, Shandong Weigao Group Medical Polymer Company Limited is a publicly traded company.

Something similar

Top by Market Cap

Same Sector

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 9.19M
Market Capitalization 21.53B
Employee 12.52K
CEO Mr. Rinan Cong
Headquarters Weihai,CN
IPO Date 2004-02-27
Website https://www.weigaogroup.com

Shandong Weigao Group Medical Polymer Company Limited engages in the research and development, production, and sale of single-use medical devices in the People's Republic of China. It operates through Medical Device Products, Orthopaedic Products, Interventional Products, Pharma Packaging Products, Blood Management Products, and Others segments. The company offers vascular and non-vascular access infusion devices, infusion sets, syringes, puncture needles, and specialized single-use clinical collection kits; wound sutures, wound healing dressings, and wound cleaning and nonvascular catheter supporting extracorporeal devices; and blood collection, storage, separation, and sterilization equipment. It also provides prefilled syringes and pre-filled flush syringes; blood collection and blood glucose testing devices; and general anesthesia consumables, local anesthesia consumables, anesthesia auxiliary consumables, ICU equipment, and open and minimally invasive surgical equipment. In addition, the company engages in the production and sale of orthopedic devices; tumor and blood vessel interventional instruments; implantation materials and artificial organs; medical PVC granules, plastic packing bags, and carton boxes; industrial automatic equipment and parts; molds; hemodialysis equipment; and type I, type II, and type III medical devices. Further, it is involved in the finance leasing and factoring business; wholesale of type I medical devices, surgical devices, and other disposal medical products; provision of asset management, enterprise consulting, enterprise management advisory services, as well as logistics and storage services, as well as export its products. The company offers its products under the Jierui, Wego Ortho, Yahua, Bangde, and Hai Xing brands. It serves hospitals, blood stations, and other medical units; and distributors. The company was incorporated in 2000 and is based in Weihai, the People's Republic of China.